Kevin Grogan
Managing Editor, Europe
Covering all aspects of the pharma industry and across all therapeutic areas, Kevin has interviewed pretty much all the leading figures in the sector. A regular attendee at financial and medical conferences (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss the industry. Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at Catholic newspaper The Universe and contributed articles to the likes of The Independent and the Manchester Evening News on football.
Latest From Kevin Grogan
Evaxion Hopes To Impress Potential Partners At ESMO
The cash-strapped Danish biotech has got some positive news flow on its vaccines for gonorrhea and melanoma and believes that Phase II data on the latter in particular will attract attention at the major oncology conference kicking off in Barcelona this week.
AstraZeneca's Hopes Still High For Tozorakimab In COPD
The company's IL-33 drug failed to improve breathing in a chronic obstructive pulmonary disease Phase II trial but benefited patients who had suffered moderate or severe exacerbations in the previous year.
Hudson Holds Reins As Sanofi Makes Strides To Become R&D Powerhouse
“For 20 or 30 years, we were not seen as a scientific leader,” the French major’s CEO tells Scrip. Now, things have started to change with several positive readouts coming out of its immunology portfolio.
Ipsen Outpaces Market With Lucrative Priority Review Voucher Deal
The going rate to buy a voucher for a faster US FDA application review is about $100m, but the France-headquartered firm received considerably more from an unnamed big pharma.
Another Boost For Valneva and Pfizer Lyme Disease Vaccine
While they wait for the results from their Phase III study, the partners have posted more impressive mid-stage data on what could be the first approved vaccine for a couple of decades to protect against infection from ticks.
Strong HERCULES Data Keep Sanofi's MS Plans Alive
Tolebrutinib has missed its goal in the GEMINI 1 and 2 trials of reducing annualised relapse rate in multiple sclerosis patients but the Paris-headquartered firm is claiming a resounding victory for the BTK inhibitor in delaying disability progression in people with non-relapsing secondary progressive MS in the HERCULES study.